Skip to main content
OpenTrials
Completed

NCT Number: NCT02737995

Iron Stores and Skeletal Muscle Metabolism in Chronic Heart Failure

Iron deficiency may contribute to exercise intolerance by altering mitochondrial oxidative capacity in skeletal muscle. Functional iron deficiency is common in heart failure patients, but the relationship to exercise intolerance and mitochondrial oxidative capacity is unknown. This is a pilot study to determine the feasibility of the use of specialized 31P-MRS and MRI techniques for measurement of skeletal muscle bioenergetics in patients with heart failure with and without functional iron deficiency.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

This study will obtain pilot feasibility data to explore the relationship between blood biomarkers of functional iron deficiency and skeletal muscle mitochondrial oxidative capacity with 31P-magnetic resonance spectroscopy (MRS) and imaging in heart failure patients.

Twenty (20) subjects will be recruited from the clinical practice of the NYU Advanced Cardiac Therapeutics group at NYU Langone Medical Center.

Twenty (20) subjects will be recruited from the practice of the NYU Advanced Cardiac Therapeutics group at NYU Langone Medical Center. The study will require a maximum of four (4) visits over a period of five (5) weeks. Eligibility for Visits 2-4 will be determined by the screening criteria in Visit 1. It is anticipated that 50% of the screened subjects at Visit 1 will be eligible to participate in Visit 2. Eligibility for participation in Visits 3 and 4 will be determined by the results of the iron biomarkers obtained at Visit 2. We anticipate that 50% of the subjects at Visit 2 will be eligible to participate in Visits 3 and 4. Only subject with functional iron deficiency will participate in Visits 3 and 4. There is no clinical care component for this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able and willing to provide written informed consent
  • Age 21-80 years
  • Chronic heart failure >3 months with NYHA Class I-III symptoms

Exclusion criteria

  • Presence of implantable defibrillator, permanent pacemaker not designed for safe use in 3T MRI stud
  • Metallic implant or implants that are deemed not suitable for MRI scan on 3T
  • Aneurysm clips, cochlear implants, presence of shrapnel in strategic locations, and metal in the eye
  • Known claustrophobia or any other history of intolerance of MRI procedure
  • Treated diabetes mellitus or hemoglobin A1c (HbA1c) >6.5%
  • Any hospitalization <60 days
  • Myocardial infarction or stroke < 6 months
  • Estimated glomerular filtration rate <30 ml/min
  • Weight <50 or >120 kg
  • Systolic blood pressure <90 mmHg or > 160 mmHg
  • Heart rate <50 or >100 beats per minute
  • Resting oxygen saturation on room air <92%
  • Hemoglobin <11 g/dl
  • Serum phosphate below normal range (<2.4 mg/dl)
  • Liver function tests (AST, ALT, Alk Phos, or Total Bilirubin) >twice upper limit of normal range
  • Pregnancy or current breastfeeding
  • Exercise limitation primarily due to valvular heart disease, lung disease, neuromuscular disease, or joint disease
  • History of asthma
  • History of anaphylaxis
  • Known history of intolerance to any formulation of intravenous iron

Treatment and study plan

Ferric carboxymaltose infusion

Drug

Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.

Primary outcomes

  1. Biomarkers of iron stores

    Time frame: 60 minutes

    Plantar flexion exercise as determined with a novel dynamic phosphorus magnetic resonance spectroscopy and imaging technique (31P-MRS & MRI) in heart failure patients (n=10) with and without functional iron deficiency. A spectrally selective three-dimensional turbo spin echo (3D-TSE) echo (3D-TSE) protocol for measurement of phosphocreatine recovery kinetics on a 3T Siemens MRI scanner as previously described (Siemens Medical Solutions, Erlangen, Germany).

  2. Skeletal muscle bioenergetics using 31P- MRS Spectroscopy

    Time frame: 120 Minutes

    Plantar flexion exercise with 31P-MRS and MRI in heart failure patients (n=5) with functional iron deficiency. A spectrally selective three-dimensional turbo spin echo (3D-TSE) protocol for measurement of phosphocreatine recovery kinetics on a 3T Siemens MRI scanner (Siemens Medical Solutions, Erlangen, Germany).

    protocol for measurement of phosphocreatine recovery kinetics on a 3T Siemens MRI scanner as previously described (Siemens Medical Solutions, Erlangen, Germany).

Secondary outcomes

  1. Functional Capacity

    Time frame: Six Minutes

    Subjects will be asked to walk along a 30 meter marked path in a corridor at a self-selected pace. Subjects will receive standardized instruction before and during the walking test. The distance walked after 6 minutes (meters) will be recorded.

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

A Pilot Feasibility Study on Iron Stores and Skeletal Muscle Metabolism in Chronic Heart Failure

Important dates

Study start
2015
Primary completion
2016
First posted
Apr 14, 2016
Registry last updated
Aug 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.